DS81 vs NSIS-B: Side-by-Side Comparison
Compare DSV (DS81) and Novonesis (Novozymes) A/S (NSIS-B) side by side: valuation, financials, growth and model signals on Bullrun.
| Metric | DS81 | NSIS-B |
|---|---|---|
| Company | DSV | Novonesis (Novozymes) A/S |
| Country / Exchange | Denmark · DU | Denmark · CO |
| Sector | Basic Materials | Basic Materials |
| Industry | Silver | Specialty Chemicals |
| Market cap | — | DKK 191.95B |
| P/E ratio | — | 43.1 |
| Dividend yield | — | 1.57% |
| Valuation model | — | 7.3% overvalued |
| Revenue (FY2025) | DKK 247.33B | EUR 4.16B |
| Revenue growth YoY | +48.0% | +8.5% |
| Net income | DKK 8.17B | EUR 583.60M |
| Gross margin | — | 53.9% |
| Diluted EPS | 34.30 | 1.25 |
Figures are in each company's reporting currency — compare growth rates and margins rather than raw amounts.